Answers are grounded in this paper and cite their sources.
Ewing sarcoma (EWS) is a malignant bone tumor or soft-tissue tumor that mainly affects children, adolescents, and young adults. Approximately half of all patients with Ewing sarcoma will at some point develop either recurrent or metastatic disease, with less than 20% of such patients surviving long-term and no new therapy in sight. Two clinical features of EWS are the EWS-FLI1 fusion oncogene and Periodic acid-Schiff (PAS) positive intracellular glycogen aggregates. While contribution of EWS-FLI1 to tumorigenesis and epigenetics has been extensively studied, the role of glycogen in EWS pathology and potentially as a therapeutic target has not been explored. Glycogen is a macro-metabolite that serves multiple roles within a cell ranging from metabolism, signaling to epigenetic regulation. Aberrant glycogen metabolism is known to drive pathogenesis in multiple neurodegenerative diseases and some cancers. Despite its vast physiological and emerging clinical significance, the lack of sensitive tools to assess glycogen severely impacted the understanding of glycogen impacts disease progression. To overcome this limitation, the Sun and Gentry laboratories developed a robust workflow utilizing matrix-assisted laser desorption/ionization (MALDI)-imaging of complex carbohydrates (MICC), a spatial technique to visualize and quantify glycogen in situ using formalin-fixed paraffin-embedded (FFPE) clinical samples. Leveraging this technique, we profiled glycogen levels in a cohort of EWS patient tumors revealing glycogen accumulation in the intra-tumoral regions across all ES samples compared with surrounding tissues. To test the therapeutic potential of targeting glycogen in EWS, we reduced glycogen levels in EWS cells (A673, TC71, TC32) using both genetic (CRISPR-Cas9) and pharmacological (guaiacol) interventions of multiple glycogen metabolism enzymes. These treatments dramatically reduced A673 EWS cell line-derived xenograft tumor growth. Glycogen metabolism is regulated by AMP-activated protein kinase (AMPK), which is a well-known tumor suppressor. AMPK kinase activity is active by metformin and metformin is currently in phase 1 and 2 clinical trials as an synergistic treatment for EWS. However, our preliminary data demonstrate that high glycogen levels in EWS inhibits AMPK and this inhibition overrides the action of metformin. Excitingly, we found that by reducing EWS glycogen levels via targeting glycogen synthase (GYS1) in A673 cells synergizes metformin action in activating AMPK and limits proliferative and clonogenic ability of these cells. Thus, moving forward, will plan to systematically test GYS1 inhibitors as a single agent, and in combination with metformin in patient-derived xenograft (PDX) or cell line-derived xenograft (CDX) EWS models to carefully evaluate efficacy and toxicity for the future planning of translation studies/clinical trials in ES patients. This study was supported by National Institute of Health (NIH) grants R35NS116824 to MSG; R01CA266004 to RCS & MSG; R01AG066653, R01AG078702, and RM1NS133593, V-Foundation Scholar, and St. Baldrick's Career Development Award to RCS; and R35GM142701 to L.C.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: